Provenge evidence 'moderate'

According to AHRQ documents released late Wednesday, there is moderately strong evidence that Provenge sipuleucel-T improves clinical outcomes in prostate cancer patients. What remains to be seen is whether the "moderate" rating in the technology assessment will lead to CMS paying for the treatment from Dendreon Corp. (NASDAQ:DNDN). The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) is scheduled to discuss the product on Nov. 17.

The reviewers did conclude there is "insufficient" evidence for Provenge in any off-label indications. The immunotherapy is approved to treat asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancer. Provenge costs $93,000 for a three-dose course of treatment. ...